Andrew Tsai

Stock Analyst at Jefferies

(0.59)
# 3,773
Out of 4,711 analysts
18
Total ratings
33.33%
Success rate
-15.82%
Average return

Stocks Rated by Andrew Tsai

Rocket Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $29
Current: $11.56
Upside: +150.87%
Marinus Pharmaceuticals
Oct 25, 2024
Downgrades: Hold
Price Target: $5$0.5
Current: $0.23
Upside: +117.39%
Sarepta Therapeutics
Oct 21, 2024
Initiates: Buy
Price Target: $165
Current: $118.97
Upside: +38.69%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5$13
Current: $0.36
Upside: +3,482.25%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $18.07
Upside: +93.69%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $3.89
Upside: +748.33%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2$15
Current: $2.50
Upside: +500.00%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.71
Upside: +319.76%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32$3
Current: $0.58
Upside: +420.83%
KE Holdings
Mar 16, 2022
Upgrades: Overweight
Price Target: $23$16
Current: $18.38
Upside: -12.95%
Initiates: Buy
Price Target: $20
Current: $1.70
Upside: +1,076.47%
Maintains: Buy
Price Target: $55$70
Current: $83.45
Upside: -16.12%
Initiates: Buy
Price Target: $27
Current: $1.19
Upside: +2,168.91%
Assumes: Buy
Price Target: $16$23
Current: $38.63
Upside: -40.46%